Trial Profile
The Safety and Utility of Skin Testing With Xolair (Omalizumab) and Placebo Omalizumab (Formulation Excipients).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jun 2017
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 11 Feb 2011 Actual end date (March 2009) added as reported by ClinicalTrials.gov.
- 11 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Nov 2008 New trial record.